We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) (CENTAUR)

This study is currently recruiting participants.
Verified November 2017 by Amylyx Pharmaceuticals Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03127514
First Posted: April 25, 2017
Last Update Posted: November 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
ALS Finding a Cure Foundation
ALS Association
Northeast ALS Consortium
Massachusetts General Hospital Neurology Clinical Research Institute
Leandro P. Rizzuto Foundation
Information provided by (Responsible Party):
Amylyx Pharmaceuticals Inc.
  Purpose
The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.

Condition Intervention Phase
Amyotrophic Lateral Sclerosis Motor Neuron Disease Neuromuscular Diseases Neurodegenerative Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases Drug: AMX0035 Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

Resource links provided by NLM:


Further study details as provided by Amylyx Pharmaceuticals Inc.:

Primary Outcome Measures:
  • ALSFRS-R Slope [ Time Frame: 24 Weeks ]
    Change in slope of ALS Functional Rating Scale over treatment duration

  • Incidence of Adverse Events [ Time Frame: 24 Weeks ]
    Comparison Between Groups of Incidence of Adverse Events Until Planned Completion

  • Proportion of subjects in each group able to remain on study drug until planned discontinuation [ Time Frame: 24 weeks ]
    A comparison of the proportion of subjects in each group able to remain on study drug until planned discontinuation between groups


Secondary Outcome Measures:
  • Accurate Testing of Limb Isometric Strength (ATLIS) [ Time Frame: 24 Weeks ]
    Change in rate of decline of isometric muscle strength over treatment duration

  • Blood-based Biomarkers [ Time Frame: 24 Weeks ]
    Change in levels of plasma-based biomarkers of neuronal death and axonal integrity from baseline to week 24

  • Slow Vital Capacity [ Time Frame: 24 Weeks ]
    Change in slope of slow vital capacity decline over treatment duration

  • Survival, tracheostomy and hospitalizations [ Time Frame: 24 Weeks ]
    Comparison of rate of occurrence between groups

  • Imaging Biomarkers [ Time Frame: 24 Weeks ]

Estimated Enrollment: 132
Actual Study Start Date: June 22, 2017
Estimated Study Completion Date: May 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo administered twice daily p.o. for 24 weeks
Other: Placebo
Matching Placebo Comparator
Experimental: AMX0035
AMX0035 administered twice daily p.o. for 24 weeks
Drug: AMX0035
AMX0035
Other Name: Tauroursodeoxycholic Acid and Sodium Phenylbutyrate

Detailed Description:
AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to demonstrate that treatment is safe, tolerable, and able to slow decline in function as measured by the ALSFRS-R. The trial will also assess the effects of AMX0035 on muscle strength, vital capacity, and biomarkers of ALS including markers of neuronal death and neuroinflammation.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Male or female, aged 18-80 years of age
  2. Sporadic or familial ALS diagnosed as definite as defined by the World Federation of Neurology revised El Escorial criteria
  3. Less than or equal to 18 months since ALS symptom onset
  4. Capable of providing informed consent and following trial procedures
  5. Slow Vital Capacity (SVC) >60% of predicted value for gender, height, and age at the Screening Visit
  6. Subjects must either not take riluzole or be on a stable dose of riluzole for at least 30 days prior to the Screening Visit. Riluzole-naïve subjects are permitted in the study.
  7. Women of child bearing potential (e.g. not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the study and 3 months after last dose of study drug. Women must not be planning to become pregnant for the duration of the study and 3 months after last dose of study drug
  8. Men must agree to practice contraception for the duration of the study and 3 months after last dose of study drug. Men must not plan to father a child or provide for sperm donation for the duration of the study and 3 months after last dose of study drug

Key Exclusion Criteria:

  1. Presence of tracheostomy
  2. Exposure to PB, TUDCA or UDCA within 3 months prior to the Screening Visit or planning to use these medications during the course of the study
  3. History of known allergy to PB or bile salts
  4. Abnormal liver function defined as AST and/or ALT > 3 times the upper limit of the normal
  5. Renal insufficiency as defined by a serum creatinine > 1.5 times the upper limit of normal
  6. Poorly controlled arterial hypertension (SBP>160mmHg or DBP>100mmHg) at the Screening Visit
  7. Pregnant women or women currently breastfeeding
  8. History of cholecystectomy
  9. Biliary disease which impedes biliary flow including active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder.
  10. History of Class III/IV heart failure (per New York Heart Association - NYHA)
  11. Severe pancreatic or intestinal disorders that may alter the enterohepatic circulation and absorption of TUDCA including biliary infections, pancreatitis and ileal resection
  12. The presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the subject to provide informed consent, according to Site Investigator judgment
  13. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the subject if they were to participate in the study
  14. Active participation in an ALS clinical trial evaluating a small molecule within 30 days of the Screening Visit
  15. Exposure at any time to any biologic under investigation for the treatment of subjects with ALS (off-label use or investigational) including cell therapies, gene therapies, and monoclonal antibodies.
  16. Implantation of Diaphragm Pacing System (DPS)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03127514


Contacts
Contact: Emily Engel, B.S. 617-724-7210 eengel@partners.org

  Show 25 Study Locations
Sponsors and Collaborators
Amylyx Pharmaceuticals Inc.
ALS Finding a Cure Foundation
ALS Association
Northeast ALS Consortium
Massachusetts General Hospital Neurology Clinical Research Institute
Leandro P. Rizzuto Foundation
Investigators
Study Director: Patrick Yeramian, MD Amylyx Pharmaceuticals Inc.
Principal Investigator: Sabrina Paganoni, MD Massachusetts General Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Amylyx Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03127514     History of Changes
Other Study ID Numbers: AMX-3500
First Submitted: April 12, 2017
First Posted: April 25, 2017
Last Update Posted: November 15, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Amylyx Pharmaceuticals Inc.:
Randomized
Double-blind
Placebo-controlled
Amyotrophic Lateral Sclerosis
Sodium Phenylbutyrate
Tauroursodeoxycholic Acid

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Neuromuscular Diseases
Neurodegenerative Diseases
Central Nervous System Diseases
Spinal Cord Diseases
TDP-43 Proteinopathies
Pathologic Processes
Proteostasis Deficiencies
Metabolic Diseases
4-phenylbutyric acid
Tauroursodeoxycholic acid
Taurochenodeoxycholic Acid
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Cholagogues and Choleretics
Gastrointestinal Agents